STAT+: Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate
STAT
OCTOBER 22, 2023
Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases. Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan.
Let's personalize your content